Science News
from research organizations

How streptococcal bacteria can be used to fight colon cancer

Date:
May 20, 2014
Source:
University of Western Ontario
Summary:
Researchers have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumor cells, they are forcing the immune system to recognize and attack the cancer. The study found the engineered bacterial toxin could significantly reduce the size of human colon cancer tumors in mice, with a drastic reduction in the instances of metastasis.
Share:
         
Total shares:  
FULL STORY

Western University researchers Dr. David Hess and Dr. John McCormick and lead author Kelcey Patterson show how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumor cells, they are forcing the immune system to recognize and attack the cancer.
Credit: Schulich School of Medicine & Dentistry, Western University

Researchers at Western University (London, Canada) have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumour cells, they are forcing the immune system to recognize and attack the cancer.

Kelcey Patterson, a PhD Candidate at Western and the lead author on the study, showed that the engineered bacterial toxin could significantly reduce the size of human colon cancer tumours in mice, with a drastic reduction in the instances of metastasis. By using mouse models that are stripped of their immune system, they were able to create a 'humanized mouse' -- one that would not only grow human colon cancer cells, but would also support a human immune system, to test the anti-cancer immunotherapy.

The work was directed by John McCormick, PhD, an Associate Professor in the Department of Microbiology and Immunology and Scientist at the Lawson Health Research Institute. "Our team has been studying these bacterial toxins called 'superantigens' for their role in bacterial infections. But we are now utilizing the power of these toxins to re-direct the immune system to go after cancer cells." McCormick says their research provides important pre-clinical evidence that this may work in humans. "This work represents a 'next-generation immunotoxin' that we hope will eventually lead to a new class of cancer therapeutic."

The research was funded by the Canadian Institutes of Health Research. Jennifer Dixon Pittaro, Peter Bastedo, David Hess and Mansour Haeryfar all contributed to the paper entitled "Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen."

McCormick and his colleagues have now received a new grant from the Cancer Research Society to develop different toxin and antibody combinations to fight other types of cancer.


Story Source:

The above story is based on materials provided by University of Western Ontario. Note: Materials may be edited for content and length.


Cite This Page:

University of Western Ontario. "How streptococcal bacteria can be used to fight colon cancer." ScienceDaily. ScienceDaily, 20 May 2014. <www.sciencedaily.com/releases/2014/05/140520120123.htm>.
University of Western Ontario. (2014, May 20). How streptococcal bacteria can be used to fight colon cancer. ScienceDaily. Retrieved April 27, 2015 from www.sciencedaily.com/releases/2014/05/140520120123.htm
University of Western Ontario. "How streptococcal bacteria can be used to fight colon cancer." ScienceDaily. www.sciencedaily.com/releases/2014/05/140520120123.htm (accessed April 27, 2015).

Share This Page:


Health & Medicine News
April 27, 2015

Latest Headlines
updated 12:56 pm ET